Download TB and Pleural Diseases - Calgary Emergency Medicine

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
TB and Pleural Diseases
Sarah McPherson
March 21, 2002
Outline

Spontaneous pneumothorax
–
–

Pleural Effusion
–
–
–

Causes
Treatment
Causes
Work up
Treatment
Tuberculosis
–
–
–
Presentation
CXR findings
management
Pneumothorax

Tension
–

Recognize, needle decompress, chest tube
Spontaneous
–
–
Primary: lean, tall males
Secondary:


more common in patient > 50 yrs
More serious because of reduced cardiopulmonary reserve
Spontaneous Pneumothorax
Causes:
Pulmonary disease

–
–
–
COPD*
Asthma
CF
Infections
–
–
–
–
Pneumonia
PCP*
TB
Lung abscess
Neoplasm
–
–
Primary lung
Metastatic
Interstitial lung disease
–
–
Sarcoidosis
Collagen vascular disease
Miscellaneous
–
–
–
–
PE
Drug abuse
Esophageal rupture
pneumoperitoneum
Spontaneous Pneumothorax

Complications:
–
–
–
–
–
Pneumomediastinum & subcutaneous emphysema
Hemopneumothorax
Reexpansion pulmonary edema
Failure to reexpand (4-14%)
Recurrence (10-50%)
Management

Small PSP(<15%) & asymptomatic
–
–
–
–
–
–
High flow oxygen for 6 hours
Repeat CXR
If no bigger then discharge home
Avoid strenuous activity
Return ASAP if dyspneic
Return in 24 hr for reassessment and repeat CXR
Spontaneous Pneumothorax Management
PSP > 15%:

Aspiration
Contraindications:
1.
Cardiopulmonary instability
2.
Significant lung disease
3.
Significant concurrent medical problem
4.
Pleural effusion
5.
Bilateral pneumothorax

Effective 70% of first PPS
Spontaneous Pneumothorax –
Aspiration
HOW TO:






Patient supine with HOB at 30 degrees
Local anesthesia at 2nd intercostal space @
midclavicular line
Advance 14 or 16 gauge angiocath cephalad until
pleural space is reached
Advance catheter and remove needle
Attach 3 way stopcock
Aspirate with 50 ml syringe
Spontaneous Pneumo - Aspiration






If > 3L aspirated insert chest tube
Repeat CXR at 6 hrs if recurrence then chest
tube
If no recurrence discharge home
Return ASAP if dyspneic
Avoid physical exertion
Return in 24 hr for repeat CXR
Spontaneous Pneumo – Chest tube
Indications:
1.
Tension pneumo
2.
Underlying pulmonary disease
3.
Significant symptoms
4.
Persistent air leak (> 3L aspirated, increase size,
recurrence)
5.
Need for positive pressure ventilation
6.
Bilateral pneumos
7.
Pleural fluid
Management of SSP

Admit

Chest tube (20-28 French)

Suction if persistent air leak or failure to
reexpand with underwater seal
NEJM.2001;342(12):868-74
Recurrent Pneumo’s

Who needs definitive management?
–
–
–
–
–
–

Failure to reexpand after 5 days
> 2 episodes on the same side
Concurrent bilateral pneumo’s
Significant hemothorax
Large bullae
High-risk vocations (aviation, divers)
What are the recurrence rates?
–
–
30%
Most recur within 6 months to 2 years from first episode
NEJM.2001;342(12):868-74
Pleural Effusions - Causes
Transudates:
 CHF
 PE
 Cirrhosis
 Hypoalbuminemia
 Myxedema
 Nephrotic syndrome
 Superior vena cava
obstruction
Exudates:








Pneumonia
TB
Connective tissue disease
Neoplasm
Uremia
Trauma
Drug induced
GI pathology (pancreatitis,
subphrenic abscess)
Pleural fluid analysis


Who do you tap?
– Unexplained effusions > 10mm on lateral decubitus
CXR
What do you send it for?
– Protein and LDH (red top)
– Glucose (red top)
– Cell count (lavender top)
– pH (blood gas tube)
– Culture and gram stain (sterile container)
– Cytology if indicated (need 5 green top tubes)
Pleural Effusions – the results

Exudative if (99% PPV):
–
–
–

LDH > 200U
Fluid-blood LDH ratio > 0.6
Fluid-blood protein level > 0.5
pH:
–
–
<7.0 is usually only in empyema or esophageal
rupture
<7.3 is with the above, parapneumonic effusions,
malignancy, RA, TB, systemic acidosis
Pleural fluid – the results

WBC
–
–
Normal < 1,000 WBC/mm3
PMNs: indicate an acute process

–
Parapneumonic effusion, PE, gastrointestinal disease,
acute TB
Monocytes: indicate a chronic process

Malignant disease, TB, PE, resolving viral pleuritis
CurrOpinPulmMed.1999;5(4):245-50
Pleural Fluid – the results

Blood
–

Low glucose
–

TB, Malignant disease, Rheumatoid disease, Parapneumonic
effusion
Elevated amylase
–

Malignancy, PE, Trauma
Pancreatitis, esophageal rupture, pleural malignancy
Elevated Adenosine diaminase (ADA)
–
TB
CurrOpinPulmMed.1999.5(4):245-50
Pleural Effusions - management


Treat underlying cause
Relieve symptoms
–
–
Therapeutic thoracentesis
Chest tube
Parapneumonic Effusion



Admit to hospital
Treat with antibiotics as per CAP
High risk PPE need drainage:
–
–
–
–
–

Purulent or putrid odor
Positive gram stain or culture
pH <7.2
Loculated on CT or US
Large effusion (1/2 hemithorax)
Low pleural pH (<7.20) in nonpurulent PPE found to
be most accurate in identifying high risk PPE
CurrOpinPulmMed.2001;7(4):193-7
Tuberculosis

Pathogenesis
– Stage 1: bacilli inhaled. Macrophage phagocytoses
if macrophage capability overcome will progress to
next phase
– Stage 2: bacilli replicate within macrophages
forming a tubercule. Lymphatic and hematogenous
spread
– Stage 3: 2-3 weeks post infection. CMI and DTH
wall off infection
– Stage 4: reactivation. Tubercule liquifies and breaks
through wall causing spread of infection and
reactivation
TB Risk Factors








Close contact with known case
Persons with HIV
Foreign-bron (Asian, African, Latin American)
Medically underserviced, low-income, homeless
Elderly
Residents of long-term care facilities
Injection drug users
Occupational exposures
TB – RFs for Reactivation











HIV
Recent TB infection (within 2 yrs)
CXR suggestive of TB that was not treated
Injection drug user
Diabetes
Silicosis
Prolonged corticosteroid use
Immunosupressive therapy
H & N cancer, hematologic disease
End-stage renal disease
Chronic malabsorption syndrome, low body weight
TB – Clinical features

Initial infection
–
–


usually asymptomatic
Clinically diagnosed with + skin test
8-10%  develop clinically active TB if no
prophylaxis
Reactivation associated with major symptoms
TB – Clinical features







Fever (night sweats)
Weight loss
Malaise
Anorexia
Cough (most common pulm TB symptom)
Hemoptysis
Infants, elderly & immunocompromised present
atypically
TB – CXR findings

Primary TB :
– Pneumonic infiltrate with hilar/mediastinal
lymphadenopathy
– Isolated mediastinal lymphadenopathy common in
children
– Miliary
– Ghon focus (calicified scar)
– Post primary lesion typically appears as an upper
lobe infiltrate with or without cavitation
– CXR can be normal in approx 10% of sputum +
patients
TB - Management

Massive hemoptysis
–
–
–
ETT intubation with #8 ETT
Position with bleeding lung dependant
Emergent consult for bronchoscopy+/-surgery
TB – medical therapy

INH, Rifampin, & pyrazinamide for 2 month
then INH for 4 more months

Preventative therapy: 10-15 mg/kg /day for 9
months
TB – preventative therapy after
inadvertent exposure



Healthy people exposed who remain – on PPD
do not need prophylaxis
If exposure is immediately known start INH x 3
month if PPD – then can stop
Conversion to, or new + PPD post exposure
need 9 month of prophylaxis